Share on StockTwits

Keryx Biopharmaceuticals (NASDAQ:KERX) CEO Ron Bentsur sold 1,788 shares of the company’s stock on the open market in a transaction dated Monday, July 7th. The stock was sold at an average price of $15.75, for a total value of $28,161.00. Following the completion of the transaction, the chief executive officer now directly owns 876,815 shares of the company’s stock, valued at approximately $13,809,836. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 15.28 on Thursday. Keryx Biopharmaceuticals has a 52-week low of $7.92 and a 52-week high of $17.46. The stock’s 50-day moving average is $14.40 and its 200-day moving average is $14.59. The company’s market cap is $1.397 billion.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.07. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $9.91 million. During the same quarter last year, the company posted ($0.03) earnings per share. Keryx Biopharmaceuticals’s revenue was up 42.9% compared to the same quarter last year. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.79 earnings per share for the current fiscal year.

A number of research firms have recently commented on KERX. Analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Friday, May 23rd. They now have a $19.00 price target on the stock. Separately, analysts at MLV & Co
cut their price target on shares of Keryx Biopharmaceuticals from $27.00 to $21.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock. Finally, analysts at Mizuho cut their price target on shares of Keryx Biopharmaceuticals from $34.00 to $32.00 in a research note on Friday, May 9th. Eight research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $24.11.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.